Hims & Hers Health announced the launch of Labs, an at‑home blood‑draw testing service that partners with Quest Diagnostics’ network of more than 1,000 collection sites nationwide. The service offers two subscription tiers: a basic plan priced at $199 per year that includes a single yearly draw covering 50 biomarker tests across nine health categories, and an advanced plan at $499 per year that provides two yearly draws covering over 120 tests across ten categories. Both plans deliver doctor‑developed action plans and the option for personalized treatment plans when appropriate.
The move extends Hims & Hers’ vertically integrated model by adding diagnostics to its existing telehealth, prescription, and wellness offerings. By feeding lab data into its AI and machine‑learning tools, the company aims to refine medication titration and health recommendations, thereby increasing the precision of its personalized care. The new service also diversifies revenue away from prescription sales, creating a recurring stream that is less sensitive to market fluctuations in drug demand.
Hims & Hers positions Labs to compete with established digital‑health platforms that already offer lab testing, such as Teladoc and GoodRx. The subscription‑based pricing and integrated care pathways are designed to deepen customer engagement, raise lifetime value, and accelerate growth in core segments like weight‑loss and dermatology. Management sees the service as a key lever for scaling the company’s technology‑driven health platform and for attracting customers interested in preventive monitoring.
Co‑founder and CEO Andrew Dudum emphasized the preventive‑care focus, saying, “With Labs, we’re bringing the benefits of data‑driven, proactive healthcare to everyone.” He added that the price point is “affordable for the majority of the country” and that the market size is “every single person in the country.” Chief Medical Officer Dr. Pat Carroll noted that lab results are central to primary‑care decision‑making and that most chronic conditions are preventable but develop before symptoms appear.
The launch is expected to become a significant revenue driver; Dudum has projected that Labs could grow into a $1 billion business. The partnership with Quest Diagnostics also provides nationwide geographic coverage, with no state‑specific limitations beyond standard provider eligibility. The service’s integration into Hims & Hers’ platform is anticipated to complement existing offerings, potentially increasing uptake of weight‑loss and dermatology plans by providing actionable health insights derived from routine testing.
The introduction of Labs signals Hims & Hers’ commitment to a comprehensive, data‑centric health ecosystem. By controlling more of the value chain—from diagnosis to treatment—the company aims to improve patient outcomes, enhance customer loyalty, and create new monetization pathways that support long‑term growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.